Translating evidence-based care into sustainable clinical practice can take years of concerted effort. Using implementation science methods can help reduce the lag time between those two steps that transform the treatment of patients.

Wearable technology, data collection, and reporting devices worn by patients on the go is the next frontier in clinical research and treatment. A host of new devices and communications technologies are poised to transform the ways researchers, clinicians, and patients collect and use data to improve patient care and outcomes.

Cystic Fibrosis didn’t even have a name until 1936. That was when Dorothy Hansine Andersen, MD, recognized the disparate symptoms of CF as a single syndrome and eventually gave it a name.

ATS President David Gozal, MD, MBA, looks back at his tenure in ATS leadership, in which he has used his previous experience traveling the world to expand the impact of ATS.

Four renowned physicians and researchers will be honored during Sunday’s Awards Session, featuring the Amberson Lecture and the presentation of the Trudeau Medal and two Distinguished Achievement Awards.

Two popular forums that celebrate diversity and the role of women in pulmonary, critical care, and sleep medicine will take place Sunday and Monday. A plated lunch will be served at both events.

ATS is leveraging new technologies to improve your experience at the International Conference. These include new functionalities on the conference app, use of beacon technology to facilitate attendee traffic flows and session attendance, and a web-based audience response system that will make sessions more interactive.

Researchers and clinicians have long recognized that environmental exposures affect lung function and dysfunction. But lung cancer, interstitial lung disease, asthma, or other chronic conditions are seldom the result of a single exposure. Susceptibility to lung disease is the cumulative effect of a lifetime of exposures from in utero through childhood and into the adult years.